AFFILIATIONS
1 Duke University School of Medicine, Durham, NC, United States
2 Genentech, Inc., South San Francisco, CA, United States
3 Genentech, Inc., South San Francisco, CA, United States
ABSTRACT
Background:
PNH is a rare, life-threatening hematologic disorder characterized by complement-mediated intravascular hemolysis, thrombosis, bone marrow failure, and substantial symptom burden. Complement inhibition has transformed PNH management, with terminal C5 inhibitors as the current standard of care and newer proximal complement inhibitors for selected pts, including those with persistent anemia or ongoing hemolysis despite C5 inhibition. Geographic differences in healthcare access and socioeconomic factors may influence tx patterns, healthcare utilization, and pt-reported outcomes (PROs), yet remain poorly characterized in PNH. The Global PNH Patient Registry was established to generate real-world evidence of the clinical characteristics, tx experience, and outcomes of pts with PNH. We present analyses of pt demographics and characteristics, examining potential disparities in care by geographic region.
Methods:
The Global PNH Patient Registry is an ongoing, prospective, longitudinal, web-based study sponsored by the Aplastic Anemia and MDS International Foundation and hosted by the National Organization for Rare Disorders. Eligible pts of any age with a diagnosis of PNH were included in the study, and data was collected between 4/28/2021 and 3/31/2026. This analysis included pts who received a complement inhibitor (terminal [eculizumab, ravulizumab, crovalimab] or proximal [pegcetacoplan, iptacopan, danicopan]) for ≥6 months (mo) and reported study outcomes for those mo. Pts were stratified by region (ex-US; US Northeast [NE], Midwest [MW], South [S], or West [W]). Outcomes included clinical characteristics, tx patterns, symptoms, healthcare utilization, cost of care, and PROs (PROs Measurement Information System [PROMIS]).
Results:
A total of 116 pts were included; 66% were female; 89 received terminal complement inhibitors and 27 proximal. Of these, 105 reported a region: 29 ex-US, 16 NE, 20 S, 19 MW, and 21 W. Most pts had completed college education (ex-US: 57%; NE and MW: 67%; S: 56%; W: 65%). Employment ranged from 52–72% across all regions. The highest household income category (>US$86,400) was reported by 13% of pts ex-US, 73% of NE pts, and 42–43% of pts across the other regions. All US pts and 76% of ex-US pts had insurance. Private insurance was held by the majority (56% ex-US; 67%-83% in the NE, MW, and W) in all regions except the S (44%).
The most common age ranges at diagnosis were 20–29 years (yrs) in the ex-US and NE, 30–39 yrs in the S and W, and 50–59 yrs in the NE and MW, with similar trends observed for age at symptom onset. Median time from symptom onset to diagnosis was 0.4–0.5 yrs across US regions and 1.4 yrs ex-US. Aplastic anemia (33%) and thrombosis (17%) were the most common comorbidities at diagnosis.
Intravenous (IV) tx predominated over oral and subcutaneous tx (proportion of complement inhibitors that was IV ranged from 70% in the S to 88% in the NE). Median tx duration ranged from 1.7 yrs in the S to 3.5 yrs in the NE. Fatigue (84%), brain fog (72%), and shortness of breath (61%) were the most frequent symptoms in the past 6 mo, with similar patterns across regions.
Across all regions, the majority of pts had a previous PNH-related hospitalization(s) at some point ever (the highest being 82% from ex-US and 74% from S), although the majority (ranging from 74% in S to 88% in MW) across all regions reported none in the past 6 mo. Among US pts only, the top reasons for hospitalizations were hemolysis (S [79%] and NE [78%] had the highest proportions) and low blood count (MW [92%] and S [79%] had the highest proportions).
Regarding costs for their PNH care (asked of US pts only), the S and W had the highest proportions reporting “quite” or “very” expensive (47% and 41%, respectively), while the NE and MW which had the lowest proportions (13% and 33%, respectively).
PROMIS scores indicated a range of proportions of pts with physical impairment (from 47% in the NE up to 83% in the S) and with pain interference (from 47% in the NE up to 67% in the S and ex-US).
Summary/Conclusion:
This analysis showed that pts with PNH receiving complement inhibitors may experience challenges associated with access and care inequities. Findings suggest geographic disparities in time to diagnosis, socioeconomic factors, cost of care, and PROs. However, as subgroup sizes were small, ongoing longitudinal analyses are needed to further explore relationships between access to healthcare, tx experience, and outcomes.
DISCLOSURES
Carlos de Castro, MD: Alexion (AstraZeneca) - Honoraria; Novartis - Honoraria; Novo Nordisk - Research Funding; Alexion (AstraZeneca) - Research Funding; Sitala - Research Funding; Genentech, Inc. - Research Funding; Apellis (Biogen) - Research Funding; BioCryst - Consultancy (Includes expert testimony); Omeros - Consultancy (Includes expert testimony); Apellis (Biogen) - Consultancy (Includes expert testimony)